A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

• Status: Completed
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn's Disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biogen
• Collaborator: Elan Pharmaceuticals
• Treatments: Natalizumab

Criteria

• Males and females 18 years of age or older

• Diagnosis of Crohn's disease for at least 6 months

• Females must not be pregnant or breastfeeding

• Must not have previously taken natalizumab

• Use of some other Crohn's disease medications is permitted, but will be closely supervised